JP2022518733A5 - - Google Patents
Info
- Publication number
- JP2022518733A5 JP2022518733A5 JP2021542102A JP2021542102A JP2022518733A5 JP 2022518733 A5 JP2022518733 A5 JP 2022518733A5 JP 2021542102 A JP2021542102 A JP 2021542102A JP 2021542102 A JP2021542102 A JP 2021542102A JP 2022518733 A5 JP2022518733 A5 JP 2022518733A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- migalastat
- salt
- cbv
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077689A JP2025128105A (ja) | 2019-01-22 | 2025-05-08 | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795524P | 2019-01-22 | 2019-01-22 | |
| US62/795,524 | 2019-01-22 | ||
| PCT/US2020/014531 WO2020154354A1 (en) | 2019-01-22 | 2020-01-22 | Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077689A Division JP2025128105A (ja) | 2019-01-22 | 2025-05-08 | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518733A JP2022518733A (ja) | 2022-03-16 |
| JP2022518733A5 true JP2022518733A5 (enExample) | 2023-01-30 |
| JP7680356B2 JP7680356B2 (ja) | 2025-05-20 |
Family
ID=69726736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542102A Active JP7680356B2 (ja) | 2019-01-22 | 2020-01-22 | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 |
| JP2025077689A Pending JP2025128105A (ja) | 2019-01-22 | 2025-05-08 | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077689A Pending JP2025128105A (ja) | 2019-01-22 | 2025-05-08 | ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220087993A1 (enExample) |
| EP (2) | EP4523750A3 (enExample) |
| JP (2) | JP7680356B2 (enExample) |
| AR (1) | AR117861A1 (enExample) |
| DK (1) | DK3914247T3 (enExample) |
| ES (1) | ES3007212T3 (enExample) |
| FI (1) | FI3914247T3 (enExample) |
| HR (1) | HRP20250078T1 (enExample) |
| HU (1) | HUE069934T2 (enExample) |
| LT (1) | LT3914247T (enExample) |
| PL (1) | PL3914247T3 (enExample) |
| PT (1) | PT3914247T (enExample) |
| RS (1) | RS66410B1 (enExample) |
| SI (1) | SI3914247T1 (enExample) |
| SM (1) | SMT202500034T1 (enExample) |
| TW (1) | TW202042812A (enExample) |
| WO (1) | WO2020154354A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3840753T (lt) * | 2018-08-20 | 2024-11-11 | Amicus Therapeutics, Inc. | Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| WO2018017721A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
-
2020
- 2020-01-20 TW TW109101869A patent/TW202042812A/zh unknown
- 2020-01-22 FI FIEP20708283.5T patent/FI3914247T3/fi active
- 2020-01-22 LT LTEPPCT/US2020/014531T patent/LT3914247T/lt unknown
- 2020-01-22 AR ARP200100155A patent/AR117861A1/es unknown
- 2020-01-22 HR HRP20250078TT patent/HRP20250078T1/hr unknown
- 2020-01-22 PL PL20708283.5T patent/PL3914247T3/pl unknown
- 2020-01-22 ES ES20708283T patent/ES3007212T3/es active Active
- 2020-01-22 EP EP24212005.3A patent/EP4523750A3/en active Pending
- 2020-01-22 RS RS20250066A patent/RS66410B1/sr unknown
- 2020-01-22 US US17/424,979 patent/US20220087993A1/en active Pending
- 2020-01-22 DK DK20708283.5T patent/DK3914247T3/da active
- 2020-01-22 WO PCT/US2020/014531 patent/WO2020154354A1/en not_active Ceased
- 2020-01-22 SI SI202030569T patent/SI3914247T1/sl unknown
- 2020-01-22 HU HUE20708283A patent/HUE069934T2/hu unknown
- 2020-01-22 EP EP20708283.5A patent/EP3914247B1/en active Active
- 2020-01-22 SM SM20250034T patent/SMT202500034T1/it unknown
- 2020-01-22 JP JP2021542102A patent/JP7680356B2/ja active Active
- 2020-01-22 PT PT207082835T patent/PT3914247T/pt unknown
-
2025
- 2025-05-08 JP JP2025077689A patent/JP2025128105A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080226715A1 (en) | Therapeutic compositions and methods | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP0397831A1 (en) | Treatment of obesity. | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| JP2020531550A5 (enExample) | ||
| EP1572206B1 (en) | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines | |
| US5753712A (en) | Treatment of migraine headaches and formulations | |
| US20200360316A1 (en) | Combination therapy using acamprosate and d-cycloserine | |
| JP2017533211A5 (enExample) | ||
| CA2403994C (en) | Nasal administration of agents for the treatment of gastroparesis | |
| EP4415701A1 (en) | Method of administering oxybate | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| JPH037218A (ja) | 薬剤組成物 | |
| FI3914247T3 (fi) | Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti | |
| WO1995022324A1 (en) | Treatment of migraine headaches and formulations | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JP2024525760A5 (enExample) | ||
| US20170087104A1 (en) | Medicament | |
| CN1165306C (zh) | 抗感冒的复方药物组合物 | |
| KR20010052895A (ko) | 치료 방법 | |
| AU2023222825A1 (en) | Medication | |
| BR112021007839A2 (pt) | tratamento e prevenção de ejaculação prematura (ep) | |
| Mentazac | Almuriva (UK); Altigmin (Turkey); Alzerta (Spain); Alzest (UK); Alzigmine (Israel).• Balaxon (Greece); Begusin (Poland). | |
| KR20210133495A (ko) | 옥수수불검화 정량 추출물 및 후박 추출물을 유효성분으로 포함하며 iLet(innovative Low excipient tablet) 기술을 이용한 정제사이즈 축소를 통해 복용 편의성이 향상된 치주질환 예방 또는 치료용 약학적 조성물 | |
| JP2005527634A (ja) | 緊張型頭痛の治療にミルナシプランを使用する方法 |